The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease
Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care.
Maria-Magdalena Patru
Maria-Magdalena Patru, MD, PhD, is an experienced physician-scientist, with over 17 years in the field of laboratory medicine and more than 14 years in the in-vitro diagnostics industry. Currently serving as the Senior Scientific Manager for neurology at Roche Diagnostics US, she leads a team developing medical strategies for neurology biomarkers, primarily focusing on Alzheimer’s. Her background includes a medical degree, Laboratory Medicine training, a PhD in Microbiology and Immunology, a clinical laboratory fellowship, and extensive experience in medical and scientific affairs, particularly in IVD product development, validation, and clinical trials.